| Literature DB >> 26498687 |
Servet Özcan1,2, Nicola Alessio3, Mustafa Burak Acar1,4, Güler Toprak1, Zeynep Burcin Gönen1, Gianfranco Peluso5, Umberto Galderisi1,3,6.
Abstract
Senescent cells secrete several molecules that help to prevent the progression of cancer. However, cancer cells can also misuse these secreted elements to survive and grow. Since the molecular and functional bases of these different elements remain poorly understood, we analyzed the effect of senescent mesenchymal stromal cell (MSC) secretome on the biology of ARH-77 myeloma cells. In addition to differentiating in mesodermal derivatives, MSCs have sustained interest among researchers by supporting hematopoiesis, contributing to tissue homeostasis, and modulating inflammatory response, all activities accomplished primarily by the secretion of cytokines and growth factors. Moreover, senescence profoundly affects the composition of MSC secretome. In this study, we induced MSC senescence by oxidative stress, DNA damage, and replicative exhaustion. While the first two are considered to induce acute senescence, extensive proliferation triggers replicative (i.e., chronic) senescence. We cultivated cancer cells in the presence of acute and chronic senescent MSC-conditioned media and evaluated their proliferation, DNA damage, apoptosis, and senescence. Our findings revealed that senescent secretomes induced apoptosis or senescence, if not both, to different extents. This anti-tumor activity became heavily impaired when secretomes were collected from senescent cells previously in contact (i.e., primed) with cancer cells. Our analysis of senescent MSC secretomes with LC-MS/MS followed by Gene Ontology classification further indicated that priming with cancer profoundly affected secretome composition by abrogating the production of pro-senescent and apoptotic factors. We thus showed for the first time that compared with cancer-primed MSCs, naïve senescent MSCs can exert different effects on tumor progression.Entities:
Keywords: Gerotarget; apoptosis; cancer; mesenchymal stem cells; secretome; senescence
Mesh:
Substances:
Year: 2015 PMID: 26498687 PMCID: PMC4741840 DOI: 10.18632/oncotarget.5430
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Biological effects of senescent MSC secretomes on myeloma cells
Panel A. Histograms depict the cell cycle profiles of ARH-77 cells incubated with control (C) or senescent secretomes; D, H, and R indicate groups treated with secretomes obtained from doxorubicin- or H202-treated and replicatively senescent MSCs, respectively. Panel B. Percentage of cycling (Ki-67+) ARH-77 cells in the presence of different secretomes. Panel C. Percentage of apoptotic ARH-77 cells following incubation with control or senescent secretomes. Panel D. Graph purporting the degree of H2AX phosphorylation evaluated by counting the number of gamma-H2AX immunofluorescent foci per cell; each foci number was determined for 200 cells; each dot represents an individual cell, while black bars indicate the mean value for each category. Panel E. Representative microscopic fields of acid β-galactosidase (blue) in ARH-77 cells; arrows indicate senescent cells. Panel F. Graph showing the mean percentage value of senescent cells. All data are shown with standard deviation. For experiments depicted in each panel, we performed one-way analysis of variance followed by Bonferroni tests for multiple comparisons. The null hypothesis assumed no difference between the experimental (D, H, R) and control groups (*p < .05, **p < .01).
Figure 2Venn diagram analysis
Top left: Venn diagram showing common and specific proteins among naïve secretomes obtained from (D) doxorubicin- or (H) H202-treated and (R) senescent replicative MSCs. Top right: Comparison of primed secretomes. Bottom: Venn diagram comparing the 264 proteins common among naïve secretomes with the 217 proteins common among primed secretomes.
Summary of Gene Ontology analysis performed with GO slims (PANTHER)
| GO Slim biological processes | GO Slim molecular functions | Go Slim protein classes | ||||||
|---|---|---|---|---|---|---|---|---|
| Naïve | Primed | Naïve | Primed | Naïve | Primed | |||
| ◊ | ◊ | ◊ | ||||||
| ◊ | ◊ | ◊ | ◊ | |||||
| ◊ | ◊ | ◊ | ◊ | |||||
| ◊ | ◊ | ◊ | ||||||
| ◊ | ◊ | ◊ | ||||||
| ◊ | ◊ | |||||||
| ◊ | ||||||||
Ontological terms classified as biological processes, molecular functions, and molecular classes; diamonds indicate the presence of a specific ontological term in either naïve or primed secretomes. The manual inspection of proteins represented with each ontological term assisted the identification of factors of the protein dataset belonging to secreted protease (SP), ECM components (E), soluble signaling factors (SF), and proteins involved in anabolic or catabolic processes (M).
Figure 3Summary of functional annotation clustering analysis (DAVID)
The clustering of ontological terms found in the naïve secretome dataset and related to A. anabolic and catabolic processes, B1. senescence and B2. apoptosis, and C. ECM formation and remodeling; D. The clustering of ontological terms found in the primed secretome dataset and related to ECM formation and remodeling.
Figure 4Canonical pathways identified with IPA
Pathways in the naïve secretome dataset associated with A. senescence and apoptosis, B. ECM formation and remodeling, and C. anabolic and catabolic processes; in green are proteins with a clear role in senescence and/or apoptosis according to data from the literature; D. Pathways in the primed secretome dataset associated with ECM formation and remodeling; in green are proteins with a clear role in cancer growth and metastasis formation.